Stockscreener 앱 받기
85.12
1.30%
1.09
시장 영업 전:
85.94
0.82
+0.96%
전일 마감가:
$84.03
열려 있는:
$84.49
하루 거래량:
1.97M
Relative Volume:
0.56
시가총액:
$33.38B
수익:
$4.15B
순이익/손실:
$535.20M
주가수익비율:
63.52
EPS:
1.34
순현금흐름:
$575.20M
1주 성능:
+0.40%
1개월 성능:
+6.40%
6개월 성능:
-2.26%
1년 성능:
-23.76%
1일 변동 폭
$84.25
$85.65
1주일 범위
$83.23
$85.90
52주 변동 폭
$57.52
$113.28
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
DXCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
85.12 | 33.24B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
DexCom Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - jammulinksnews.com
What drives DexCom Inc. stock priceExtraordinary market timing - Autocar Professional
What analysts say about DexCom Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Is DexCom Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com
We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease - simplywall.st
DexCom: Delivering Consistent Growth (NASDAQ:DXCM) - Seeking Alpha
Still Too Pricey? Dexcom’s Double-Digit Growth May Not Be Enough (DXCM) - Seeking Alpha
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years - AOL.com
Dexcom recalls 19 models of glucose monitoring receivers - Modern Healthcare
Dexcom’s Recall of Certain CGM Receivers is Class I - Medical Product Outsourcing
Foletta sells Dexcom (DXCM) shares worth $234,216 - Investing.com Australia
Foletta sells Dexcom (DXCM) shares worth $234,216 By Investing.com - Investing.com Canada
FDA updates recall of certain Dexcom CGM speakers (DXCM) - Seeking Alpha
Assessing the Impact of Dexcom's Critical Device Recall on Its Market Position and Investor Sentiment - AInvest
Dexcom recalls glucose monitor receivers due to alert failure risk - Investing.com
Dexcom recalls glucose monitor receivers due to alert failure risk By Investing.com - Investing.com UK
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews - Cadillac News
DexCom (DXCM) Target Price Raised by Mizuho Analyst | DXCM Stock News - GuruFocus
Analyst recommendations: Airbnb, Dexcom, Gitlab, AMD, Citigroup… - MarketScreener
Morgan Stanley Adjusts DexCom Price Target to $89 From $82, Maintains Equal Weight Rating - MarketScreener
Beyond The Numbers: 8 Analysts Discuss DexCom Stock - Benzinga
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
When Should You Buy DexCom, Inc. (NASDAQ:DXCM)? - 富途牛牛
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga
DexCom, Inc. (DXCM) Stock Analysis: Evaluating a 18.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Ravens’ Mark Andrews leads first Dexcom U Signing Day Camp, inspiring young athletes with diabetes - WMAR 2 News Baltimore
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. - Barron's
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day - Investegate
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
What You Need To Know Ahead Of DexCom’s Earnings Release - Barchart.com
Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push - MSN
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Nasdaq
3 Reasons Growth Investors Will Love DexCom (DXCM) - Yahoo Finance
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. - BioSpace
DexCom (DXCM) Leads Healthcare Sector Gains - GuruFocus
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.14%
0.34%
자본화:
|
볼륨(24시간):